XOMA (NASDAQ:XOMA) Price Target Lowered to $104.00 at HC Wainwright

XOMA (NASDAQ:XOMA) had its price objective cut by equities research analysts at HC Wainwright from $123.00 to $104.00 in a report issued on Monday,Benzinga reports. The brokerage currently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s price objective indicates a potential upside of 290.83% from the company’s previous close.

Separately, StockNews.com upgraded shares of XOMA from a “sell” rating to a “hold” rating in a research report on Thursday, January 16th.

XOMA Stock Performance

Shares of XOMA opened at $26.61 on Monday. The firm has a 50-day moving average price of $27.84 and a 200 day moving average price of $28.09. The firm has a market capitalization of $313.47 million, a PE ratio of -7.65 and a beta of 0.90. The company has a quick ratio of 7.52, a current ratio of 7.52 and a debt-to-equity ratio of 1.28. XOMA has a 52-week low of $19.50 and a 52-week high of $35.00.

XOMA (NASDAQ:XOMA) last announced its earnings results on Thursday, November 7th. The biotechnology company reported ($0.39) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.05. The firm had revenue of $7.20 million during the quarter, compared to analyst estimates of $6.66 million. XOMA had a negative net margin of 151.34% and a negative return on equity of 24.95%. On average, sell-side analysts anticipate that XOMA will post -1.41 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other XOMA news, major shareholder Bvf Partners L. P/Il sold 500,742 shares of the firm’s stock in a transaction dated Friday, January 24th. The shares were sold at an average price of $26.10, for a total value of $13,069,366.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Owen Hughes sold 21,881 shares of the firm’s stock in a transaction dated Wednesday, November 13th. The stock was sold at an average price of $29.95, for a total transaction of $655,335.95. Following the completion of the transaction, the chief executive officer now owns 34,979 shares of the company’s stock, valued at approximately $1,047,621.05. The trade was a 38.48 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 7.20% of the company’s stock.

Hedge Funds Weigh In On XOMA

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Geode Capital Management LLC raised its position in XOMA by 0.6% during the third quarter. Geode Capital Management LLC now owns 182,741 shares of the biotechnology company’s stock valued at $4,840,000 after acquiring an additional 1,138 shares in the last quarter. Barclays PLC grew its holdings in XOMA by 300.7% during the third quarter. Barclays PLC now owns 11,256 shares of the biotechnology company’s stock valued at $298,000 after purchasing an additional 8,447 shares during the last quarter. BNP Paribas Financial Markets grew its holdings in XOMA by 95.0% during the third quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company’s stock valued at $43,000 after purchasing an additional 795 shares during the last quarter. State Street Corp grew its holdings in XOMA by 1.2% during the third quarter. State Street Corp now owns 142,857 shares of the biotechnology company’s stock valued at $3,783,000 after purchasing an additional 1,754 shares during the last quarter. Finally, Ellsworth Advisors LLC acquired a new position in XOMA during the third quarter valued at approximately $516,000. Institutional investors own 95.92% of the company’s stock.

XOMA Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.